trimetrexate has been researched along with Antibody Deficiency Syndrome in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Smit, MJ | 1 |
| De Groot, R | 1 |
| Van Dongen, JJ | 1 |
| Van der Voort, E | 1 |
| Neijens, HJ | 1 |
| Whitfield, LR | 1 |
1 other study available for trimetrexate and Antibody Deficiency Syndrome
| Article | Year |
|---|---|
Trimetrexate efficacy and pharmacokinetics during treatment of refractory Pneumocystis carinii pneumonia in an infant with severe combined immunodeficiency disease.
Topics: Antifungal Agents; Drug Combinations; Glucuronates; Humans; Immunologic Deficiency Syndromes; Infant | 1990 |